Persons with mild cognitive impairment (MCI) have overt changes in thinking and memory, but they are still largely independent in daily affairs. They have a far higher rate of developing dementia (progressing to a more debilitating state of cognitive impairment) than cognitively normal persons, but at the individual patient level, prognosis is variable. Sometimes persons with MCI do not worsen and a few even revert back to cognitive normality. 1, 2 The variable prognosis in MCI is one reason why the term "MCI" has caught on: not only does it denote a sense of severity at the mildest level, it also conveys uncertainty of prognosis. Identification of the subset of patients with MCI at highest risk to progress to more severe cognitive impairment is a very important goal for research and future clinical care. Quantitating the degree of cognitive impairment by traditional history-taking, brief mental status testing, and more detailed neuropsychological assessment are necessary and informative first steps. However, knowledge of cognitive and functional status in MCI still leaves much uncertainty regarding the ability to predict worsening.
The identification of biomarkers for the pathophysiology of Alzheimer disease (AD) has changed risk prediction for future AD dementia. New criteria for MCI due to AD that incorporated biomarkers were published in 2011 by a workgroup sponsored by the National Institute on Aging (NIA) and Alzheimer's Association (AA). 3 The approach to the biomarker diagnosis of AD was based on a model 4 that made specific predictions about the sequence in which biomarkers became abnormal in AD. The underlying assumption was that subjects with MCI who have biomarker evidence of AD are more likely to decline than those who lack abnormal biomarkers. The model characterized the biomarkers as those representing b-amyloidosis (b-amyloid biomarkers) and those representing neuronal and synaptic dysfunction (neurodegeneration biomarkers or brain injury biomarkers). 4 CSF b-amyloid 42 and amyloid PET imaging measure brain b-amyloidosis; the 2 are strongly inversely correlated. 5 The brain injury biomarkers are represented by CSF total or phospho-tau protein levels, glucose hypometabolism as measured by 18 fluorodeoxyglucose (FDG)-PET, and atrophy measured by volumetric MRI. Other brain injury biomarkers are also being evaluated.
Since the introduction of amyloid imaging in 2004, relationships of b-amyloidosis, neuronal injury biomarkers, and cognition have been under intensive investigation. Longitudinal observations have allowed the inference that b-amyloid biomarkers become abnormal years before persons develop dementia due to AD. [6] [7] [8] The age distribution of AD-like levels of b-amyloidosis in cognitively normal individuals anticipates the prevalence of dementia by ;15 years. b-amyloid abnormalities correlate relatively weakly with cognitive function. [6] [7] [8] The observations from amyloid imaging could have been anticipated by CSF studies and autopsy studies, but it took the independent observations from amyloid imaging to validate the concept that the initial expression of brain bamyloidosis precedes overt cognitive impairment. On the other hand, while brain injury biomarker changes can be observed in cognitively normal individuals, their appearance and progression are strongly correlated with cognitive decline, 6 paralleling neuropathologic observations. 9 In the current issue of Neurology ® , Prestia et al. 10 tested the predictive power of the NIA-AA model of MCI for incident dementia over a variable period of observation ranging from a few months to 7 years. They defined pathologic b-amyloid (amyloid1) using CSF b-amyloid 42 values considered AD-like based on prior studies (ranging from ,450 to ,550 pg/mL across the 3 participating centers). They used 2 brain injury biomarkers-FDG-PET and hippocampal atrophy-and defined abnormality for each using cutoff values referenced to a normal elderly group. As predicted by the NIA-AA diagnostic hierarchy, 3 the joint presence of abnormal amyloid and abnormal brain injury biomarkers conferred a much higher risk for progression to dementia than did the presence of amyloid1 alone, and far greater risk than no biomarker abnormalities.
The observations of Prestia et al. supported key aspects of the NIA-AA approach. They showed that b-amyloidosis must be accompanied by a certain level of brain injury to convey the highest risk for progression to dementia. The observations parallel those in other series of patients with MCI 11, 12 and those in cognitively normal persons. 13 There are many studies, including a very recent one, 14 showing that patients with MCI who are amyloid1 have a higher risk for cognitive decline than patients with MCI who lack abnormal levels of b-amyloid. The observations of Prestia et al. clearly demonstrate that brain injury biomarkers amplify the risk. The difference in outcomes between amyloid1/ brain injury -and amyloid1/brain injury1 patients with MCI suggests that future investigations should stratify amyloid1 subjects based on their possession of brain injury biomarkers. If amyloid imaging in MCI were to enter clinical practice on a widespread basis, the differential predictive power may be important for patients and families. Furthermore, if therapies that delayed the biological progression of AD became available, we would not want to treat all patients with MCI with anti-AD therapies, but only those with the AD biomarker-defined risk.
Prestia et al. also showed that the 30% of patients with MCI who have no abnormal biomarkers had a very favorable prognosis. Whether the patients in the biomarker-negative group have a static cognitive disorder can be ascertained only with longer follow-up, but the fact that nearly a third of the MCI group fell into this category makes the point that patients with MCI are a heterogeneous group.
Prestia et al. also encountered a pattern of biomarker changes that was left undefined in the NIA-AA criteria. About a fifth of the patients with MCI were amyloid2 but brain injury1. This group had a higher risk for incident dementia than the amyloid1/brain injury2 group and about the same as the group with amyloid1 and only one abnormal brain injury biomarker. The amyloid2/brain injury1 pattern has previously been labeled in studies of cognitively normal persons as suspected non-Alzheimer pathology (sNAP). 15 In cognitively normal persons falling into the sNAP group, prognosis after 15 months was more favorable than in cognitively normal persons who were amyloid1/ brain injury1. 13 The reasons for the difference between sNAP MCI and sNAP cognitively normal persons are unclear. In MCI, at least, amyloid2/brain injury1 carried risk for progression of cognitive impairment.
The findings of Prestia et al. represent the first chapter of a longer work, which the authors readily acknowledge. A longer follow-up could result in a different risk profile. The slight difference in MiniMental State Examination among persons who progressed vs those who did not raises a concern that initial disease severity influenced the results. The cutpoints for the brain injury biomarkers could arguably have been defined differently, and in any case, what to make of disagreements among brain injury biomarkers is unresolved. In the MCI subgroup that was amyloid1, hippocampal atrophy and FDG-PET biomarkers disagreed in 27/47 (57% of the time). Having both brain injury biomarkers abnormal conferred much greater risk than only one, but is one brain injury biomarker more informative than the other? The NIA-AA panel acknowledged that they lacked sufficient evidence to address the issue. 3 There is no doubt that biomarkers for AD are going to change how the disease is viewed, but much more work remains to determine their optimal use and bring them into routine clinical practice. 
STUDY FUNDING

